4D-310 is under clinical development by 4D Molecular Therapeutics and currently in Phase II for Fabry Disease. According to GlobalData, Phase II drugs for Fabry Disease have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 4D-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

4D-310 overview

4D-310 is under development for the treatment of fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that uses 4D-C102 Adeno-associated virus (AAV) vector variant carrying a transgene encoding a lysosomal enzyme alpha-galactosidase A (GLA) gene. It acts by targeting lysosomal enzyme alpha-galactosidase A (GLA).

4D Molecular Therapeutics overview

4D Molecular Therapeutics is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s pipeline products include 4D-125, 4D-110, 4D-150, 4D-135, 4D-310 and 4D-710. It has developed a technology platform, Therapeutic Vector Evolution that empowers to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. 4D Molecular Therapeutics develops pipeline products that targets therapeutic areas such as liver, retina, heart, brain, skeletal muscle, and lung, among others. The company works in partnership with F. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 4D Molecular Therapeutics is headquartered at Emeryville, California, the US.

For a complete picture of 4D-310’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.